Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Hiroyuki Kushida
Observed names:
H Kushida,
Hiroyuki KUSHIDA
Institution:
Osaka Minami Medical Center
Observed institutions:
Kobe Pharmaceutical University,
Osaka National Hospital,
Osaka Minami Medical Center,
National Hospital Organization,
National Hospital Organization Minami Kyoto Hospital
ORCID:
0009-0000-8554-0687
Observed ORCIDs:
0009-0000-8554-0687,
0000-0002-3847-4610
OpenAlex ID:
A5060896860
Impact of UGT1A1 gene polymorphisms on plasma dolutegravir trough concentrations and neuropsychiatric adverse events in Japanese individuals infected with HIV-1
2017
·
Hiroki Yagura
, Dai Watanabe
, et al.
·
BMC Infectious Diseases
·
101
PDF
Assessing recovery of renal function after tenofovir disoproxil fumarate discontinuation
2011
·
Munehiro Yoshino
, Hiroki Yagura
, et al.
·
Journal of Infection and Chemotherapy
·
20
Correlation between UGT1A1 polymorphisms and raltegravir plasma trough concentrations in Japanese HIV-1-infected patients
2015
·
Hiroki Yagura
, Dai Watanabe
, et al.
·
Journal of Infection and Chemotherapy
·
15
Evaluation of plasma doravirine concentrations in patients with HIV-1 undergoing hemodialysis
2023
·
Hiroyuki Kushida
, Dai Watanabe
, et al.
·
Journal of Infection and Chemotherapy
·
4
Thermal Stability of Tenofovir Disoproxil Fumarate in Suspension
2014
·
Hiroki Yagura
, Mayu Shibata
, et al.
·
Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)
·
4
Association between tenofovir plasma trough concentrations in the early stage of administration and discontinuation of up to five years tenofovir disoproxil fumarate due to renal function-related adverse events in Japanese HIV-1 infected patients
2024
·
Hiroki Yagura
, Dai Watanabe
, et al.
·
Journal of Pharmaceutical Health Care and Sciences
·
3
Dual drivers of polypharmacy in people with HIV : Quantifying the independent associations of aging and long‐term antiretroviral therapy
2025
·
Shigeru Hasebe
, Taiki Kusaka
, et al.
·
HIV Medicine
·
1
Stability of anti-HIV Agents in Suspension
2012
·
Hiroki Yagura
, Mayu Shibata
, et al.
·
Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)
·
1
PDF
Abacavir-Containing Versus Abacavir-Free Dolutegravir-Based Regimens: A Cardiovascular Pharmacovigilance Analysis
2026
·
Shigeru Hasebe
, Masayuki TANAKA
, et al.
·
Current HIV Research
From Priority Need to Evidence-to-Action: A Structured Narrative Review of Six Purposefully Selected Anti-Infective Innovations
2026
·
Shigeru Hasebe
, Masayuki Tanaka
, et al.
·
Pharmacoepidemiology
Report-Level Comparator-Definition Sensitivity in FAERS Cardiometabolic Disproportionality Analysis: A Long-Acting Cabotegravir/Rilpivirine HIV Pharmacovigilance Case Study
2026
·
Shigeru Hasebe
, Chihiro Nishikawa
, et al.
·
Pharmacoepidemiology
Comprehensive Cardiovascular Risk Profiling in People Living with HIV: Insights from the Japanese Adverse Drug Event Report Database
2025
·
Shigeru Hasebe
, Masayuki Tanaka
, et al.
·
AIDS Research and Human Retroviruses
Changes in the Plasma Concentrations of Tenofovir in a Hemodialysis Patient with HIV-1 and HBV Co-infection:A Case Report
2021
·
Hiroyuki KUSHIDA
, Takao NAKAUCHI
, et al.
·
Kansenshogaku zasshi
PDF
P17.29 UGT1A1*6 polymorphisms are predictive of high plasma concentrations of dolutegravir in Japanese individuals
2015
·
H Yagura
, D Watanabe
, et al.
·
Sexually Transmitted Infections
PDF
Show more works
View as search
Works count:
14
Citation count:
149
H-index:
4
I10-index:
3
Year
Topic
Type